Market News How it works Learn FAQ
| RCT 0.0827 8.67% | NU 12.59 -16.95% | EWZ 34.15 -19.82% | BBD 2.93 -28.01% | TGL 0.2427 9.57% | AZTR 1.53 113.99% | ITUB 7.7 -20.37% | XP 15.705 -48.36% | NVD 3.99 -4.77% | SRTM 0.3 -30.28% | WFF 0.0898 12.25% | SPCX 146.9 -0.40% | PBR 22.5 -13.99% | SHFS 0.094 -29.00% | SOXL 90.5 8.31% | INTC 90.47 4.04% | VALE 12 -3.23% | NVDA 216 2.39% | CLRO 4.97 52.92% | NOK 8.64 6.14% | JBLU 2.37 -9.71% | TSLL 10.76 10.25% | CRWV 55.19 1.76% | GCDT 0.1545 -12.27% | SOXS 47.98 -8.54% | RIG 6.53 1.87% | NWGL 0.0869 5.98% | ABEV 2.83 -14.24% | RWM 14.5 -0.34% | BITO 10.65 -1.66% | AAL 12.2 0.74% | GPUS 0.1785 5.68% | TSLG 5.38 10.47% | T 20.85 -0.38% | SGRY 23.25 47.62% | IREN 25.43 2.11% | INTR 4.68 -34.91% | SBS 4.73 -26.09% | NFLX 63.9 -2.96% | GRAB 2.71 -2.87% | TSLA 391.62 5.21% | QID 14.22 -2.27% | WULF 11.98 5.83% | TQQQ 68.43 3.23% | CIFR 7.71 -2.90% | RBNE 0.17 -10.53% | SID 0.9118 -22.73% | SPDN 8.5 -0.47% | VZ 43.1 -3.49% | LUCD 0.5007 21.82%
THTheseus Pharmaceuticals, Inc. logo

Theseus Pharmaceuticals, Inc. (THRX)

NASDAQ Global Select · Currency in USD
$4.07 ▲ +0.01 (+0.12%)
At close: Feb 13, 3:59 PM ET. Market closed.

Summary

Previous Close
$4.06
Open
$4.06
Day's Range
$4.06 – $4.07
52 Week Range
$2.05 – $12.37
Volume
677,694
Avg. Volume
435,815
Market Cap
$181.50M
Beta (5Y Monthly)
3.98
PE Ratio (TTM)
--
EPS (TTM)
-$1.22
Earnings Date
--
Forward Dividend & Yield
$1.00 (24.60%)
Ex-Dividend Date
Sep 8, 2015
1y Target Est
--

Profile: Theseus Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
38
CEO
Iain D. Dukes DPHIL,

Theseus Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and bringing to market targeted treatments for cancer patients. Their leading investigational compound, THE-630, is a pan-KIT inhibitor undergoing Phase I clinical trials for treating gastrointestinal stromal tumors. The company is also advancing a fourth-generation EGFR inhibitor specifically designed to combat the C797S EGFR mutation, which confers resistance to initial or later-line osimertinib therapy in individuals with non-small cell lung cancer.

Earnings

DateEst.Actual
Mar 14, 2024-$0.33-$0.35Miss
Nov 17, 2023-$0.35-$0.31Beat
Aug 10, 2023-$0.34-$0.34Beat
May 11, 2023-$0.42-$0.34Beat
Mar 9, 2023-$0.44-$0.35Beat
Nov 3, 2022-$0.34-$0.38Miss

Analyst view

Rating: Buy
Buy 67% · Hold 33% · Sell 0%

Get free alerts on THRX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.